Nautilus Biotechnology, Inc.

Biotech gives us another useful comparison.

On October second, Stocks to Trade reported that Nautilus Biotechnology's stock climbed after the company landed a peer-reviewed paper in Nature Methods for its Voyager platform and iterative mapping technology.

The platform is designed to read proteins at the single molecule level and distinguish different proteoforms of the same protein.

Why does this matter for an AI and markets episode? Because biotech investors understand something AI investors are relearning: platform claims need validation milestones.